Search Results
Your search for japan matches 645 pages
Showing 101 - 150Individualized SABR for Lung Tumors
In a phase II study (iSABR) reported in JAMA Oncology, Gensheimer et al found that individualized stereotactic ablative radiotherapy (SABR) for up to four lung cancer tumors was associated with a high degree of local control and the ability to minimize radiation doses. Study Details Two hundred and ...
Tucatinib/Trastuzumab for Previously Treated Patients With HER2-Positive Metastatic Biliary Tract Cancer
As reported in the Journal of Clinical Oncology by Nakamura et al, findings in a cohort of the phase II SGNTUC-019 basket study showed that tucatinib plus trastuzumab was active in previously treated patients with HER2-positive metastatic biliary tract cancer who had not received prior...
DESTINY-Lung02: T-DXd for HER2-Mutant Metastatic NSCLC
As reported in the Journal of Clinical Oncology by Goto et al, primary results of the phase II DESTINY-Lung02 trial have shown activity of fam-trastuzumab deruxtecan-nxki (T-DXd) in patients with HER2-mutant metastatic non–small cell lung cancer (NSCLC) previously treated with platinum-containing...
Adjuvant Pemetrexed/Cisplatin vs Vinorelbine/Cisplatin in Stage II–IIIA Nonsquamous NSCLC
In a 5-year analysis of the Japanese phase III JIPANG trial reported in the Journal of Clinical Oncology, Kenmotsu et al found no significant differences in overall or recurrence-free survival with adjuvant pemetrexed/cisplatin vs vinorelbine/cisplatin in patients with stage II–IIIA nonsquamous...
AEGEAN Trial: Addition of Perioperative Durvalumab to Neoadjuvant Chemotherapy in Resectable NSCLC
The addition of perioperative durvalumab to neoadjuvant chemotherapy may be associated with a tolerable surgical safety profile and may not adversely impact surgery in patients with resectable non–small cell lung cancer (NSCLC), according to new findings presented by Mitsudomi et al at the...
AI-Based Tool Aids in Diagnosis of Cervical Cancers and Precancers
A new artificial intelligence (AI)-based diagnostic tool for colposcopy examinations may improve the accuracy of diagnosing cancerous and precancerous cervical lesions, including cervical intraepithelial neoplasia (CIN), according to a retrospective validation study presented at the 2023 ASCO...
Predicting Recurrence in Colorectal Cancer Using Postoperative Circulating Tumor DNA Dynamics
Postoperative molecular residual disease detected by circulating tumor DNA (ctDNA) at 4 weeks after resection has emerged as the strongest prognostic risk factor for disease-free survival in patients with resected colorectal cancer. This finding was observed regardless of BRAF V600E status and...
Rising After Struggle: Surviving My First ASCO Breakthrough in Japan
After a year of hard work preparing a strong abstract for the prestigious 2023 ASCO Annual Meeting, I finally received an acceptance letter from the scientific committee. I was overjoyed to see the efforts of our multinational team being rewarded. A few moments later, I received the decision...
LEAP-017: No Significant Benefit for Lenvatinib Plus Pembrolizumab in Non–MSI-H/dMMR Metastatic Colorectal Cancer
In the final analysis of the phase III LEAP-017 study, the combination of lenvatinib plus pembrolizumab failed to improve outcomes over the standard of care in previously treated patients with metastatic colorectal cancer that lacked high microsatellite instability or mismatch repair deficiency...
Updates on Cancer Therapies Under Study From 2023 ASCO Breakthrough
Presented here are some brief summaries of novel therapies under study from the 2023 ASCO Breakthrough meeting in Yokohama, Japan. The subjects range from new observations about a HER2-directed bispecific antibody and systemic treatment of gastric cancer to an option for treating hand-foot syndrome ...
Noninvasive, Multitarget Stool DNA Methylation Assay Under Study in Early Detection of Multiple Gastrointestinal Cancers
A prospective study in China found that a noninvasive, multitarget stool DNA methylation assay was accurate in the early detection and identification of the tissue of origin of gastrointestinal cancers.1 The study, conducted by Li-Yue Sun, MD, of Guangdong Second Provincial General Hospital,...
Liquid Biopsy Assay Demonstrated Effectiveness in Early Cancer Detection in Asymptomatic Individuals in Vietnam
A Vietnamese prospective study by Hanh Thi-Hue Nguyen, BS, and Le Son Tran, PhD, both of the Medical Genetics Institute and Gene Solutions, Ho Chi Minh City, Vietnam, and colleagues, investigating the feasibility and performance of a circulating tumor DNA (ctDNA) analyzing test in the early...
Expert Point of View: Caron Jacobson, MD
Caron Jacobson, MD, shared some comments on ZUMA-7 with The ASCO Post. She called ZUMA-7 “an extremely important study to advance the care of high-risk early relapsing or primary refractory large B-cell lymphoma after front-line chemoimmunotherapy.” Dr. Jacobson is Assistant Professor of Medicine...
On the Art of Organizing Best of ASCO Meetings
Preparing and running a medical conference is usually a complex but rewarding mission. It is a demanding job that is typically done voluntarily by physicians and educators who are dedicated to professional and community service; advancement of research and education; as well as the dissemination of ...
Noninvasive Multitarget Stool DNA Methylation Assay in the Early Detection of Multiple Gastrointestinal Cancers
With an estimated 4.8 million new cases and 3.4 million deaths worldwide recorded in 2018, cancers of the gastrointestinal tract account for over one-quarter (26%) of global cancer incidence and over one-third (35%) of all cancer-related deaths. Although the U.S. Food and Drug Administration (FDA)...
Liquid Biopsy Assay Demonstrates Effective Early Cancer Detection in Asymptomatic Individuals in Vietnam
Studies show that both the incidence of cancer and mortality rates in Vietnam have tripled over the past 3 decades; in 2020, over 182,560 new cases of cancer were diagnosed in the country, and nearly 123,000 people died from the disease. In addition, most cases—up to 80%—are diagnosed at an...
Gilteritinib Maintenance Therapy After Transplantation in Patients With FLT3-ITD AML Who Have Measurable Residual Disease
A new therapeutic option is under study for use in a difficult-to-treat subset of patients with acute myeloid leukemia (AML), according to a presentation during the European Hematology Association (EHA) 2023 Hybrid Congress.1 Exploratory results of the phase III MORPHO trial showed a benefit to the ...
Can an AI-Based Tool Accurately Detect Precancerous Cervical Lesions?
Researchers in Japan have developed an artificial intelligence (AI)-based diagnostic tool for colposcopy examinations that may accurately identify cervical intraepithelial neoplasia (CIN) and subsequently suggest appropriate biopsy sites. The research will be presented by Ueda et al at the 2023...
Exercise May Reduce Sexual Dysfunction Caused by Prostate Cancer Treatment
A combination of resistance and aerobic exercise may improve sexual function in patients with prostate cancer, according to a new study conducted in Australia. The research was presented by Galvao et al at the 2023 ASCO Breakthrough meeting (Abstract 71) in Yokohama, Japan. “Sexual dysfunction is a ...
Expert Point of View: Barbara Pistilli, MD
Barbara Pistilli, MD, Head of the Breast Cancer Unit in the Medical Oncology Department of Gustave Roussy Cancer Center, Villejuif, France, was invited to discuss the TROPiCS-02 updated analysis. She began by pointing out that the target landscape of antibody-drug conjugates is “expanding...
Adjuvant Osimertinib in Resected EGFR-Mutant NSCLC: Overall Survival Analysis of the ADAURA Trial
As reported in The New England Journal of Medicine by Masahiro Tsuboi, MD, and colleagues, the planned final overall survival analysis of the phase III ADAURA trial has shown a significant benefit with osimertinib vs placebo in patients with resected EGFR-mutant non–small cell lung cancer (NSCLC)....
How ASCO’s 2023 Breakthrough Meeting Is Putting a Spotlight on Cutting-Edge Advances in Cancer Care Technology and Innovation
After a 4-year hiatus because of the COVID-19 pandemic, ASCO’s Breakthrough meeting is returning to Asia from August 3–5, 2023, in Yokohama, Japan, and will also be livestreamed (https://conferences.asco.org/breakthrough/welcome). Launched in 2019 in Bangkok, Thailand, “Breakthrough is ASCO’s...
Expert Point of View: Caron Jacobson, MD
Caron Jacobson, MD, shared some comments on ZUMA-7 with The ASCO Post. She called ZUMA-7 “an extremely important study to advance the care of high-risk early relapsing or primary refractory large B-cell lymphoma after front-line chemoimmunotherapy.” Dr. Jacobson is Assistant Professor of Medicine...
Expert Point of View: Kohei Shitara, MD and Bradley Alexander McGregor, MD
At the ASCO session on the phase II DESTINY-PanTumor02 trial on T-DXd, the invited discussant, Kohei Shitara, MD, commented: “As expected, this trial demonstrated a very impressive response rate and duration of response” and “showed T-DXd [fam-trastuzumab deruxtecan-nxki] to be a potential new...
DESTINY-PanTumor02: Is T-DXd Heading for Tumor-Agnostic Status?
Fam-trastuzumab deruxtecan-nxki (T-DXd) may prove to be beneficial in a variety of treatment-refractory solid tumors that express HER2, according to findings from the international phase II DESTINY-PanTumor02 trial presented at the 2023 ASCO Annual Meeting.1 For patients with the highest HER2...
TROP-2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Advanced NSCLC
In a phase I study (TROPION-PanTumor01) reported in the Journal of Clinical Oncology, Shimizu et al described outcomes with the trophoblast cell-surface antigen 2 (TROP-2)-directed antibody-drug conjugate datopotamab deruxtecan at the dose selected for further development in patients with advanced...
Patients With Refractory Metastatic Colorectal Cancer May Experience Survival Benefits With Fruquintinib
Targeted therapy with fruquintinib may improve overall survival and progression-free survival in patients with refractory metastatic colorectal cancer, according to a novel study published by Dasari et al in The Lancet. Background According to the American Cancer Society, colorectal cancer is the...
Global Funding for Cancer Research: 2016–2020
In a study reported in The Lancet Oncology, McIntosh et al identified components of global funding for cancer research—both public and philanthropic—between 2016 and 2020. Study Details The study used data from the UberResearch Dimensions database and Cancer Research UK data on human cancer...
The Second-Generation Son of Greek Immigrants, the First to Go to College, Becomes a Leader in Sarcoma Research and Treatment
George D. Demetri, MD, FASCO, Director of the Sarcoma Center at Dana-Farber Cancer Institute, and Professor of Medicine and Co-Director of the Ludwig Center at Harvard, was born in Hyde Park, a town along the Hudson River in New York. When Dr. Demetri was growing up there, it was known for three...
Making the Art of Oncology and Cancer Care Central to Her Presidential Term
Lynn M. Schuchter, MD, FASCO, has said that volunteering and working with ASCO over many years has been the highlight of her career. She served on the ASCO Board of Directors from 2009 to 2012 and on several ASCO committees, including terms as Chair of the Annual Meeting Scientific Program...
Cancer-Specific Mortality Rates Vary Widely Across the Globe, Study Finds
Investigators have found that in the majority of countries studied, the recent mortality rates for all major cancer types have decreased except for lung cancer among female patients and hepatic cancer among male patients—where increasing rates were observed in most countries, according to a novel...
Extension of Adjuvant Anastrozole After Initial Therapeutic Regimen in Postmenopausal Patients With Hormone Receptor–Positive Breast Cancer
In a Japanese phase III trial (AERAS) reported in the Journal of Clinical Oncology, Iwase et al found that an additional 5 years of adjuvant anastrozole after 5 years of anastrozole or tamoxifen followed by anastrozole was associated with improved disease-free survival vs no further anastrozole...
GLOW Trial: Zolbetuximab Plus Chemotherapy Sets New Treatment Standard in Gastric Cancer Subset
In the first-line setting, the monoclonal antibody zolbetuximab in combination with chemotherapy extended overall survival in patients with claudin-18.2 (CLDN18.2)-positive, HER2-negative, locally advanced or metastatic gastric adenocarcinoma. This regimen is now positioned as a new standard of...
T-DXd in HER2-Expressing Advanced or Recurrent Uterine Carcinosarcoma
In a Japanese phase II trial (STATICE) reported in the Journal of Clinical Oncology, Nishikawa et al found that fam-trastuzumab deruxtecan-nxki (T-DXd) showed activity in patients with HER2-expressing advanced or recurrent uterine carcinosarcoma. Study Details In the multicenter trial, 32 evaluable ...
Interaction of H pylori Infection and Germline Pathogenic Variants in Risk for Gastric Cancer
In a Japanese study reported in The New England Journal of Medicine, Usui et al found that Helicobacter pylori infection affected the risk of gastric cancer in patients with predisposing germline pathogenic variants, including variants in homologous recombination genes. As stated by the...
Abstracts of Interest on Novel Therapies for Gastrointestinal Cancers
As in the years before the COVID-19 pandemic, the 2023 ASCO GI Cancers Symposium—its 20th such gathering—played to a full ballroom. It featured a stellar lineup of experts in the field as well as high-quality, impactful research in esophageal, gastric, hepatocellular, pancreatic, biliary tract, and ...
Encorafenib, Binimetinib, and Cetuximab in Previously Untreated Patients With BRAF V600E–Mutant Metastatic Colorectal Cancer
In the phase II ANCHOR CRC trial reported in the Journal of Clinical Oncology, Eric Van Cutsem, MD, PhD, and colleagues found that the combination of encorafenib, binimetinib, and cetuximab produced an objective response in nearly half of previously untreated patients with BRAF V600E–mutant...
Quick Takes on Important Cancer Research From ASH 2022
The high-energy vibe at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition reflected the welcomed presence of enthusiastic on-site attendees and the high quality of the research presented. The ASCO Post has already reported in detail on many of these presentations, and now...
Subset of Patients With Advanced Gastric Cancer May Benefit From Claudin18.2-Targeted Agent Zolbetuximab
Initial data from the global phase III SPOTLIGHT trial may herald the use of a new targeted agent for a subset of patients with advanced gastric or gastroesophageal junction adenocarcinoma.1 The addition ofzolbetuximab, which targets the transmembrane protein claudin18.2 (CLDN18.2), to chemotherapy ...
Adjuvant S-1 vs Observation for Resected Biliary Tract Cancer
In a Japanese phase III trial (JCOG1202, ASCOT) reported in The Lancet, Nakachi et al found that adjuvant S-1 was associated with significantly improved overall survival vs observation in patients with resected biliary tract cancer. Study Details The multicenter, open-label trial included 440...
Subset of Patients With Advanced Gastric/GEJ Cancer May Benefit From CLDN18.2-Targeted Drug Zolbetuximab: SPOTLIGHT Study
Initial data from the global phase III SPOTLIGHT trial could herald the use of a new targeted agent for a subset of patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. First-line treatment with zolbetuximab, which targets the transmembrane protein claudin 18.2...
Effect of Adjuvant Chemotherapy on Survival in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy
In a retrospective matched-cohort study reported in JAMA Oncology, Sugawara et al found that receipt of adjuvant chemotherapy improved survival vs no adjuvant chemotherapy in patients with pancreatic adenocarcinoma who received curative-intent surgery following multiagent neoadjuvant chemotherapy....
Patients With Breast Cancer Who Interrupted Endocrine Therapy to Pursue Pregnancy Did Not Experience Worse Short-Term Recurrence Rates
Patients with breast cancer who paused their endocrine therapy while attempting to conceive experienced short-term rates of breast cancer recurrence similar to patients with breast cancer who did not pause their therapy for pregnancy—and many of them went on to conceive and deliver healthy babies,...
5-Year Outcomes With Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma
In an individual patient meta-analysis reported in The Lancet Oncology, Shankar Siva, PhD, and colleagues found that patients receiving stereotactic ablative body radiotherapy (SABR) for primary localized renal cell carcinoma had long-term outcomes indicating that the treatment is safe and...
C.S. Pramesh, MS, FRCS, Seeks to Bring Equity to India’s Sprawling Cancer Care System
In this installment of The ASCO Post’s Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with C.S. Pramesh, MS, FRCS, Director of the Tata Memorial Hospital and Professor and Head of Thoracic Surgery at the Tata Memorial Centre, Mumbai, India. Dr. Pramesh is the Convener of the...
Longer-Term Follow-up From ADAURA Supports Adjuvant Osimertinib as Standard of Care for EGFR-Mutated Stage IB to IIIA NSCLC
With longer-term follow-up, adjuvant treatment with osimertinib led to a 77% reduction in the risk of disease recurrence or death following complete resection vs placebo-treated patients with EGFR-mutated, stage II to IIIA non–small cell lung cancer (NSCLC). Disease-free survival was improved...
Short Course of Radiotherapy With Concurrent Radiation Boost for High-Risk, Early-Stage Breast Cancer
A 3-week course of radiation therapy including a concomitant boost of radiation to the surgical site appears to be as safe and effective as 4 to 6 weeks of radiation therapy given with a sequential boost of radiation for patients with early-stage breast cancer who have a high risk of recurrence....
Phase III FRESCO-2 Trial of Fruquintinib Meets Primary Endpoint in Metastatic Colorectal Cancer
HUTCHMED (China) Limited recently announced that the global phase III FRESCO-2 trial evaluating the investigational use of the anti–vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor fruquintinib met its primary endpoint of overall survival in patients with advanced, refractory...
Lisocabtagene Maraleucel Improves Event-Free Survival in Second-Line Treatment of Relapsed or Refractory LBCL
As reported in The Lancet by Manali Kamdar, MD, of the University of Colorado Cancer Center, Aurora, and colleagues, an interim analysis of the phase III TRANSFORM trial has shown significantly improved event-free survival with second-line lisocabtagene maraleucel vs standard-of-care salvage...
Effect of Smartphone Psychotherapy Apps on Fear of Recurrence Among Young Breast Cancer Survivors
In a Japanese trial (J-SUPPORT 1703) reported in the Journal of Clinical Oncology, Akechi et al found that 8-week use of smartphone psychotherapy apps was associated with significant benefits in reducing the fear of recurrence in breast cancer survivors aged 20 to 49 years. Study Details In the...
